can undergo remarkable and reversible phenotypic modulation characterized by decreased expression of SMC differentiation marker proteins, such as SM myosin heavy chain and SM α-actin, 7 whose expression is coordinately downregulated through activation of transcription factors that promote phenotypic modulation, including Krüppel-like factor 4 (KLF4), KLF5 and early growth response 1, [7] [8] [9] and through suppression of a coactivator, myocardin, which promotes SMC differentiation. 10 Phenotypically modulated SMCs proliferate, migrate, and produce various paracrine factors, extracellular matrix, and matrix proteases, thereby promoting remodeling of the vascular wall. Several cytokines have been shown to induce phenotypic modulation in SMCs, and recent studies also indicate that lipids enriched in oxidized low-density lipoprotein, including lysophosphatidylcholine, lysophosphatidic acid, and oxidized phospholipids, exert effects on the SMC phenotype. [11] [12] [13] However, little is known about the effects of fatty acids on SMCs.
A growing body of evidence suggests that ROS function as important signaling molecules and play physiological and pathological roles within blood vessels. The major sources of ROS in SMCs are NADPH oxidases, 14 the catalytic subunits of which are Nox family proteins. The predominant NOX isoforms in rat aortic SMCs are NOX1 and NOX4, which have distinct functions and are differentially regulated. NOX1 seems to be involved in the control of proliferation, migration, and extracellular matrix production in SMCs. 15 For example, SMC-specific overexpression of NOX1 augments aortic medial hypertrophy induced by angiotensin II, 16 whereas that effect, as well as wire injury-induced neointima formation, is diminished in Nox1-deficient mice. 15, 17 By contrast, NOX4 seems to be critical for the maintenance of the differentiated state of SMCs. 18 Toll-like receptors (TLRs) are pattern-recognition receptors that initiate innate immune responses on recognition of a wide range of pathogen-associated molecular patterns, including lipids, lipoproteins, and proteins. In addition to their essential role in host immune defense, a growing body of evidence suggests that they are capable of responding to noninfectious insults and modulating inflammatory processes in cardiovascular and metabolic diseases. 19 The expression of TLR2 and TLR4 is elevated in vascular lesions and has been shown to be involved in the formation of vascular lesion in several animal models. 20 For instance, Apoe −/− mice deficient in Tlr4 exhibit reduced lesion area and macrophage recruitment. 21 Furthermore, recent studies demonstrated that vascular SMCs express functional TLR4 that can respond to lipopolysaccharide and activate nuclear factor (NF)-κB signaling. 22, 23 Interestingly, TLR4 reportedly recognizes saturated fatty acids, 19 although it remains unclear whether this possible response of TLR4 to saturated fatty acids is involved in the progression of vascular disease.
For the present study, we developed a novel method to specifically increase palmitate levels in the circulation of mice and found that palmitate markedly aggravates neointima formation, in part, by inducing phenotypic modulation in SMCs. In addition, we show that TLR4/NF-κB signaling responds to palmitate and induces ROS-mediated production of proinflammatory mediators by upregulating Nox1 expression. Collectively, these findings demonstrate the essential role played by novel signaling mechanisms that regulate the SMC phenotype in response to saturated fatty acids in vascular disease.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Palmitate Aggravates Neointima Formation
To investigate the effect of FFAs on neointima formation, we first established a method to increase serum palmitate levels in mice. Because ethyl palmitate has been shown to be rapidly hydrolyzed to free palmitate in the blood of rodents, 24, 25 we developed a method to administer ethyl palmitate, which entailed dissolving it with lecithin and administering it intraperitoneally. Serum palmitate levels were significantly increased by a single intraperitoneal administration of emulsified ethyl palmitate ( Figure 1A ), indicating that ethyl palmitate was indeed hydrolyzed to palmitate and that it entered the systemic circulation. Through daily administration of ethyl palmitate (0.6 mg/g of ethyl palmitate), serum FFA levels were increased ≈2-fold by day 5 ( Figure 1B ). The serum palmitate levels were increased by ≈160 μmol/L after 3 weeks of daily ethyl palmitate administration ( Figure 1C ). In addition, palmitoleate (C16:1n-7) and myristate (C14:0) were also significantly increased, presumably reflecting palmitate metabolism. Serum triglyceride levels were increased by ≈3-fold on day 5 compared with the levels in the vehicle group, but cholesterol levels did not significantly differ between the 2 groups (Figure I in the online-only Data Supplement).
We then used a vascular injury model entailing ligation of the common carotid artery in C57BL/6J mice (8-week-old male) to compare the effects of administering ethyl palmitate or vehicle daily for 3 weeks. Ligation of common carotid artery near carotid bifurcation is known to induce proliferation of medial SMCs, leading to extensive neointima formation in the presence of an intact endothelial lining. 26 After harvesting the arteries, we found that vehicle-treated mice had only modest neointimal lesions containing a few layers of cells and that neointima formation was markedly aggravated by ethyl palmitate administration ( Figure 1D and 1E).
Immunohistochemical staining ( Figure 1D ) showed that most of the neointimal cells in both vehicle-and palmitate-treated animals were positive for SM α-actin (actin, alpha 2, smooth muscle, aorta [ACTA2]). However, although intimal and medial SMCs exhibited similar levels of SM α-actin staining in the vehicle-treated mice, many intimal SMCs exhibited lower levels of SM α-actin staining than medial SMCs in the palmitate-treated mice. Furthermore, although the majority of neointimal cells in the palmitate-treated group showed weak or no staining for the SM1 isoform of SM myosin heavy chain (myosin, heavy polypeptide 11, smooth muscle [MYH11]), many more neointimal cells stained positively for SM1 in the vehicle group ( Figure 1D ). These findings suggest that palmitate aggravates neointimal lesions by promoting phenotypic modulation of SMCs.
Palmitate Promotes Phenotypic Modulation of Vascular Smooth Muscle
Because palmitate-induced neointima primarily contained phenotypically modulated SMCs, we next tested whether palmitate would induce phenotypic modulation in cultured rat aortic SMCs. Cultured rat SMCs were treated with 200 μmol/L of palmitate, which did not affect the viability of Figure 2A ). However, palmitate stimulated expression of Klf5, encoding a transcription factor involved in the control of phenotypic modulation, and Srf, encoding a transcription factor involved in the expression of a subset of SMC genes. 7 Also upregulated was the transcription of Pdgfb, encoding platelet-derived growth factor B, and Mmp3 and Mmp9, encoding matrix metalloproteinases 3 and 9, 2 enzymes involved in SMC proliferation and vascular remodeling 27 (Figure 2A ). The expression levels of these genes were dose-dependently affected by palmitate within a range of 50 to In addition, consistent with this gene expression profile, bromodeoxyuridine assays showed that palmitate enhanced DNA synthesis in SMCs ( Figure IIB in the online-only Data Supplement). Collectively, these findings indicate that palmitate induces phenotypic modulation in cultured SMCs.
Palmitate-Induced ROS Are Involved in SMC Phenotypic Modulation
Given that palmitate is known to induce oxidative stress in pancreatic β cells and skeletal muscle cells, 28, 29 we hypothesized that oxidative stress might be involved in the palmitate-induced phenotypic modulation. To test that idea, we used 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate to measure intracellular ROS levels. We found that palmitate significantly increased ROS levels and that the increase in ROS could be suppressed using the antioxidant N-acetylcysteine ( Figure 2B ). We also measured ROS levels using lucigenin and again found that ROS levels were increased by palmitate and suppressed by N-acetylcysteine ( Figure 2C ).
To determine whether the elevated ROS levels contribute to phenotypic modulation, SMCs were treated with palmitate and N-acetylcysteine. N-acetylcysteine significantly suppressed the increases in the expression of Klf5, Pdgfb, Mmp3, and Mmp9 ( Figure 2D ), although its suppression of Klf5 was modest, and it did not reverse the palmitate-mediated inhibition of Acta2 and Myh11 expression. This suggests that palmitate-induced ROS production mediates, at least in part, the modulation of gene expression in SMCs, particularly genes involved in inflammatory processes. It is likely, however, that additional signaling pathways are involved in inhibiting SMC differentiation marker genes in response to palmitate.
Palmitate Upregulates Nox1
NADPH oxidases are the major source of ROS in SMCs. 30 To assess the involvement of NADPH oxidases in palmitateinduced phenotypic modulation, we first examined the effect of the NADPH oxidase inhibitor apocynin. We found that apocynin suppressed palmitate-induced expression of Klf5, Pdgfb, Mmp3, and Mmp9 ( Figure 3A ), but it did not mitigate the inhibition of Acta2 and Myh11 expression. Another NADPH inhibitor, diphenyleneiodonium, similarly suppressed the response to palmitate ( Figure III in the online-only Data Supplement).
Among the Nox family NADPH oxidases, NOX1 and NOX4 are the major isoforms expressed in rodent SMCs. NOX proteins form multimeric complexes with p22 phox and other subunits, including p47 phox and NoxA1. Of those, only Nox1 transcription was increased by palmitate in SMCs ( Figure 3B and Figure IVA in the online-only Data Supplement), and there was a corresponding increase in NOX1 protein ( Figure 3C ). Furthermore, when ethyl palmitate was administered to mice, there was an increase in aortic expression of Nox1 ( Figure 3D ). By contrast, ethyl palmitate had no significant effect on Nox4 expression ( Figure IVB in the online-only Data Supplement).
To determine the role of NOX1 expressed in response to palmitate, Nox1 expression was knocked down using a specific small interfering RNA. Knocking down Nox1 significantly reduced ROS levels in palmitate-treated SMCs ( Figure 3E ) and significantly inhibited palmitate-induced upregulation of Klf5, Pdgfb, Mmp3, and Mmp9 ( Figure 3F ) although it did not reverse the inhibition of Acta2 and Myh11 by palmitate. Protein levels of the genes were similarly affected by palmitate and Nox1 knockdown ( Figure 3G ). Taken together, these findings suggest that upregulation of Nox1 expression is important for palmitate-induced induction of ROS and the genes involved in inflammation.
TLR Signaling Mediates Palmitate-Induced Upregulation of Nox1
We next investigated the signaling mechanism by which palmitate induces Nox1 expression. Because saturated fatty acids reportedly activate TLR4 signaling in macrophages, 31 we assessed the involvement of TLR4 in the SMC response to palmitate. When either Tlr4 or its central adapter, Myd88, was knocked down, levels of Nox1 were significantly reduced in palmitate-treated cells ( Figure 4A ). Knocking down Tlr4 and Myd88 also significantly reduced ROS levels in palmitatetreated SMCs ( Figure 4B ), which suggests that TLR4/MyD88 signaling is essential for palmitate-induced ROS production in SMCs. Knocking down Tlr4 and Myd88 also significantly suppressed palmitate-induced upregulation of Pdgfb, Mmp3, and Mmp9 ( Figure 4C and 4D) , although the expression of Acta2 and Myh11 was not restored, as was expected from the results obtained with antioxidant treatment and Nox1 knockdown. The inability of Tlr4 and Myd88 knockdown to suppress induction of Klf5 also suggests that an additional palmitate-activated pathway may be involved in upregulating Klf5.
NF-κB Controls Nox1 Transcription in Response to Palmitate
TLR4/MyD88 signaling is known to activate NF-κB. We, therefore, assessed the possible involvement of NF-κB signaling in the palmitate response. IκB kinase phosphorylation was observed beginning 8 hours after palmitate treatment in SMCs, and peak levels were detected at 16 hours ( Figure 5A ). In addition, levels of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha, the degradation of which is induced by IKK-mediated phosphorylation, were diminished beginning 8 hours after palmitate treatment ( Figure 5A ). Degradation of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha enables translocation of NF-κB into the nucleus, and, as expected, nuclear levels of the p65 subunit of NF-κB began to rise 8 hours after palmitate treatment ( Figure 5B ). Furthermore, the induced nuclear accumulation of p65 was suppressed by knocking down Tlr4 and Myd88 expression ( Figure 5C ), suggesting that palmitate activates NF-κB signaling in SMCs via TLR4/MyD88.
Nox1 levels were increased beginning 16 hours after palmitate treatment ( Figure 5D ), later than NF-κB activation, suggesting that NF-κB might mediate Nox1 upregulation. To test this possibility, NF-κB signaling was inhibited using BMS-345541, a highly selective inhibitor of IκB kinase. 32 BMS-345541 significantly inhibited both the upregulation of Nox1 and the production of ROS induced by palmitate ( Figure 5E and 5F) , and, as expected, it also markedly To further define the mechanism by which NF-κB activates Nox1 expression, we tested whether NF-κB directly controls its transcription. The 500-bp region 5′ from the translation start site is highly conserved across humans, mouse, and rat, and the transcription initiation site of human Nox1 was reportedly located −187 bp from the translation start site. 33 The high homology between the region extending from the transcription start site to the translation start site in humans and rat Figure 2 . B, Relative levels of Nox1 and Nox4 mRNA in SMCs treated for 24 h with palmitate or vehicle. C, Expression of NOX1 protein analyzed by Western blotting. β-Tubulin was used as a loading control. D, Relative levels of Nox1 mRNA in aortas from mice administered ethyl palmitate or vehicle for 10 days. Expression levels were normalized first to those of 18s rRNA and then further normalized to the levels in the vehicle-treated animals. n=6 and 10 for the vehicle and ethyl palmitate groups, respectively. SMCs were transfected with small interfering RNA (siRNA) against Nox1 (siNox1) or control siRNA (siCtrl), after which reactive oxygen species (ROS) levels were analyzed using the cells treated with palmitate or vehicle for 24 h (E). Relative mRNA levels were analyzed as in Figure 2 (68.4% identity in −200 to +30 bp) suggests that the transcription start site in rat Nox1 is at or near −187 bp from the translation start site. We, therefore, first constructed a luciferase reporter driven by the region −500 to −4 bp from the translation start site of rat Nox1 (pGL3-500Nox1). This −500/−4 bp fragment was capable of driving luciferase expression in SMCs, and its activity was significantly augmented by palmitate ( Figure 5G ). In addition, BMS-345541 abolished activation of the −500/−4 bp region by palmitate ( Figure 5G ), suggesting that NF-κB signaling is required for transactivation of the Nox1 promoter.
To determine the subregions responding to palmitate, we generated a series of Nox1 promoter deletion mutants ( Figure 5H ). Although reporter constructs driven by the −400/−4-and −300/−4-bp regions were activated by palmitate, the −200/−4-bp region did not respond to palmitate, suggesting that a palmitate-responsive element is located within a region extending from −300 to −200 bp. Notably, there is a conserved potential NF-κB-binding site within this region at −263 bp ( Figure VI in the online-only Data Supplement). Furthermore, although mutation of this site within the −400/−4-bp region (pGL3-400Nox1μκB) did not significantly affect basal reporter activity in untreated SMCs ( Figure 5I) , it completely abolished the response of the promoter to palmitate ( Figure 5I ), indicating that this NF-κB element is important for palmitate-dependent transactivation of the Nox1 promoter. This was confirmed by chromatin immunoprecipitation assays, which showed that, in response to palmitate, NF-κB bound to the Nox1 promoter ( Figure 5J and  5K) . Thus, the rat Nox1 promoter is apparently transactivated by NF-κB in response to palmitate.
TLR4/MyD88 Mediates Palmitate-Induced Exacerbation of Neointima Formation
Finally, we tested whether TLR4/MyD88 signaling is required for exacerbation of neointima formation by palmitate in vivo. When palmitate was administered daily to Myd88 knockout mice as shown in Figure 1 , it did not significantly increase aortic levels of Nox1 mRNA ( Figure 6A ). In the carotid artery ligation model, deletion of Myd88 did not significantly affect neointima formation compared with the wild types in the vehicle-treated groups (Figure 6B and 6C ). However, Myd88 −/− mice exhibited much reduced neointima formation compared with wild types treated with palmitate, demonstrating that TLR4/MyD88 signaling is required for palmitate-induced neointima formation in vivo. The TLR4/MyD88 pathway is important for immune cell function, raising the possibility that the absence of TLR4/ MyD88 signaling in bone marrow (BM)-derived cells, such as macrophages, might underlie the reduced neointima formation observed in Myd88 −/− mice. We assessed this possibility using Myd88 −/− mice whose BM was replaced with wild-type BM. Compared with the wild-type mice with wild-type BM, the Myd88 −/− mice with wild-type BM exhibited significantly suppressed neointima formation ( Figure 6D and 6E) , indicating that wild-type BM cells were not sufficient to reverse the suppressed neointima formation in Myd88 −/− . These results demonstrate that Myd88 in vascular cells is essential for the response to ethyl palmitate infusion in vivo.
Discussion
In the present study, we used a novel method based on administration of ethyl palmitate to increase circulating free palmitic acid levels in mice. This enabled us to clearly show that the major long-chain saturated FFA, palmitate, aggravates neointima formation. Our identification of the molecular mechanism by which palmitate induces phenotypic modulation in SMCs further confirms that palmitate directly contributes to the progression of vascular disease. Several clinical studies have demonstrated that diets high in saturated fatty acids lead to increased circulating FFA levels and are linked to higher risks of cardiovascular disease. 34, 35 Anderson et al 36 recently reported that a plasma fatty acid profile characterized by higher proportions of palmitate, palmitoleic, and oleic acids and lower proportions of linoleic, dihomo-γ linoleic, and arachidonic acids is associated with increased aortic pulse wave velocity and cardiovascular mortality. These findings, along with the results of the present study, strongly suggest that saturated fatty acids, including palmitate, are clinically relevant pathological mediators of cardiovascular disease, especially in subjects with obesity or metabolic syndrome.
Results of the present study demonstrate that palmitate, the major FFA in circulation, modulates SMC phenotype. Previous reports have also described the effects of lipids on SMCs, which are enriched in oxidized low-density lipoprotein, such as lysophosphatidylcholine, lysophosphatidic acid, and oxidized phospholipids. For instance, Owens' group showed in a series of studies that oxidized 1-palmitoyl-2-arachidonoyl-snglycero-3-phosphorylcholine induces phenotypic modulation of SMCs, leading to suppression of SMC differentiation marker genes and concomitant increases in the expression of chemokine and type VIII collagen genes, in part via activation of KLF4. 12, 37 In addition, Johnstone et al 13 showed that oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholines reduce connexin 43 expression and promote SMC proliferation. Unsaturated lysophosphatidic acid (LPAs) have also been shown to induce phenotypic modulation in SMCs. 38 For instance, brief exposures to LPAs induced neointima formation in uninjured carotid arteries and aggravated balloon injury-mediated neointima formation. 11 In line with the effect of LPAs, mice deficient in both LPA1 and LPA2 receptors showed much reduced neointima formation. 39 Thus, lipids are clearly important regulators of SMC phenotype.
Palmitate modulated the SMC phenotype by reducing the expression of differentiation marker genes (eg, Myh11 and Acta2) and inducing the expression of proinflammatory genes (eg, Mmp3/9 and Pdgfb; Figure 2 ). In addition, we found that palmitate activated ROS signaling by inducing Nox1 via the TLR4/MyD88/NF-κB pathway (Figures 3-5 ). Inhibition of this pathway using small interfering RNAs against Tlr4, Myd88, and Nox1 or pharmacological inhibitors of ROS, NOX1, and NF-κB reduced the expression of the proinflammatory genes. However, those genetic and pharmacological interventions did not reverse the suppression of differentiation marker genes, and their effects on Klf5 were variable. Collectively, the results indicate that the TLR4/NF-κB pathway activated by palmitate primarily contributes to induction of the proinflammatory phenotype in SMCs, whereas an additional pathway may mediate palmitate-induced dedifferentiation of SMCs. Previous studies have shown that palmitate induces endoplasmic reticulum stress, 40 and endoplasmic reticulum stress is reportedly increased in intimal SMCs from Ldlr −/− mice. 41 It has also been shown that the mitogen-activated protein kinase and p38 mitogen-activated protein kinase pathways activate Klf5 expression. 42 It will be interesting to assess the possible involvement of those mechanisms in the phenotypic modulation of SMCs.
Our results demonstrate that TLR4 is essential for palmitateinduced NF-κB activation and ROS production, which are in turn important for induction of proinflammatory phenotypes in SMCs. Previous studies have reported that angiotensin II upregulates Tlr4 expression in cultured SMCs 43 and that TLR4 mediates induction of monocyte chemotactic protein-1 and interleukin-6 in response to lipopolysaccharide and palmitate in SMCs. 44 Recently, Song et al 45 reported that TLR4 is partly responsible for the enhanced basal expression of interleukin-6 in aged SMCs. These results further support the notion that the TLR4 signaling is crucially involved in the control of SMC phenotype and gene expression in response to environmental cues, including FFAs. In addition to SMCs, TLR4 was also shown to be important for endothelial responses to various stimuli. For instance, Kim et al 3 reported that brief ex vivo incubation of isolated mouse aortic tissue with palmitate induced NF-κB activation and impaired endothelial insulin signaling. This was not observed in Tlr4 −/− tissue, 3 which suggests that TLR4 mediates at least some of the effects of palmitate on endothelial cells. Furthermore, the pivotal involvement of TLR4 in innate immune responses in macrophages is well established. 46 These findings strongly suggest that TLR4 is one of the key sensor molecules sensing environmental cues during the development of vascular disease.
In the present study, we focused on the effect of palmitate on SMCs because the neointimal lesions seen in the carotid artery ligation model we used primarily contained phenotypically modulated SMCs. The finding that wild-type BM was not capable of reversing the suppression of palmitate-induced neointima formation in Myd88 −/− mice further supports the notion that TLR4/MyD88 signaling in vascular cells, including SMCs, is essential for the vascular response to palmitate. It is well known, however, that many cell types, including endothelial cells and macrophages, are involved in neointima formation. Interestingly, we previously found that palmitate induces paracrine factors in macrophages, which promote SMC proliferation. 47 It is, therefore, possible that in other disease models palmitate may have more prominent effects on these other cell types.
In summary, our results demonstrate that palmitate is crucially involved in vascular pathology through induction of inflammatory phenotypes in SMCs, which is in part mediated by the TLR4/MyD88/NF-κB/NOX1/ROS pathway. Because serum levels of saturated FFAs are increased in obese subjects and those with metabolic syndrome, the molecular pathway identified in the present study could provide attractive therapeutic targets for the prevention of atherosclerosis in such subjects. Accumulation of excess lipids in metabolic tissues, including liver and muscle, leads to insulin resistance, cellular dysfunction, and cell death, which is collectively termed lipotoxicity. 48 Results of the present study indicate that vascular lipotoxicity that activates inflammatory processes is likely to contribute to vascular diseases, such as atherosclerosis. Therefore, our findings strongly suggest that FFAs are an important pathogenic factor that affects both cardiovascular and metabolic tissues.
